NetworkNewsBreaks – Predictive Oncology (NASDAQ:
Post# of 281
(Total Views: 167)
Posted On: 02/02/2021 4:28:51 PM
NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. Litchfield Hills Research strictly follows FINRA standards for quality and objectivity, and the research firm has certified that the publication is compliant with FINRA research rules 2241, 3110. In addition, Litchfield confirmed that the report has been reviewed by a supervisory senior analyst and is MiFID II compliant as well as classified as minor non-monetary benefit under MiFID II. In the announcement it was noted that Litchfield develops its price target, financial models, peer comparisons and investment thesis without input from management of the company.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. Litchfield Hills Research strictly follows FINRA standards for quality and objectivity, and the research firm has certified that the publication is compliant with FINRA research rules 2241, 3110. In addition, Litchfield confirmed that the report has been reviewed by a supervisory senior analyst and is MiFID II compliant as well as classified as minor non-monetary benefit under MiFID II. In the announcement it was noted that Litchfield develops its price target, financial models, peer comparisons and investment thesis without input from management of the company.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼